The human brain revisited: Opportunities and challenges in postmortem studies of psychiatric disorders

Neuropsychopharmacology

Volumn 26, Issue 2, 2002, Pages 143-154

  Lewis, David A ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Brain banks; Clinical diagnosis; Postmortem interval; Schizophrenia

Indexed keywords

NEUROFILAMENT PROTEIN; PSYCHOTROPIC AGENT; SOMATOSTATIN 14; SOMATOSTATIN 28;

AUTOPSY; BRAIN FUNCTION; BRAIN TISSUE; CLINICAL FEATURE; COGNITIVE DEFECT; ENZYME ACTIVITY; GENOMICS; HUMAN; IMMUNOREACTIVITY; MENTAL DISEASE; NEUROBIOLOGY; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEOMICS; PSYCHIATRIC DIAGNOSIS; REVIEW; SCHIZOPHRENIA; TOXICOLOGY;

EID: 0036146670     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00393-1     Document Type: Article

References (55)

1. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
2. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia
3. Heterogeneity of layer II neurons in human entorhinal cortex
4. Post mortem structural analyses of schizophrenic brain: Study designs and the interpretation of data
5. Two-dimensional versus three-dimensional cell counting: A practical perspective
6. PET and MRI of the thalamus in never-medicated patients with schizophrenia
7. Effect of pre- and postmortem variables on specific mRNA levels in human brain
8. Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder
9. The neuropathology of schizophrenia: A critical assessment of research methodologies
10. Reduced glial cell density and neuronal size in anterior cingulate cortex in major depressive disorder
11. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use
12. Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
13. Postnatal development of tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in monkey rostral entorhinal cortex
14. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
15. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia
16. Thalamic volumes in patients with first-episode schizophrenia
17. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: Regional and diagnostic specificity
18. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder
19. Quantification without pontification: Choosing a method for counting objects in sectioned tissues
20. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia
21. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia
22. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: Selective mRNA vulnerability and comparison with their encoded proteins
23. Methodological issues
24. A comparative analysis of the distribution of prosomatostatin-derived peptides in human and monkey neocortex
25. Cerebral ventricular size and cognitive impairment in chronic schizophrenia
26. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophenia: A possible neurochemical basis for 'hypofrontality'
27. Validity of DSM-III-R diagnosis by psychological autopsy: A comparison with clinician ante-mortem diagnosis
28. Tissue pH is an indicator of mRNA preservation in human post-mortem brain
29. Four isoforms of tyrosine hydroxylase are expressed in human brain
30. Expression and distribution of two isoforms of tyrosine hydroxylase in macaque monkey brain
31. Cortical dopamine in schizophrenia: Strategies for postmortem studies
32. Gene expression in human alcoholism: Microarray analysis of frontal cortex
33. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex
34. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia
35. Analysis of complex brain disorders with gene expression microarrays: Schizophrenia as a disease of the synapse
36. Glial reduction in the subgenual prefrontal cortex in mood disorders
37. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics
38. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia
39. The influence of agonmortem human brain tissue
40. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects
41. Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex in subjects with schizophrenia
42. Neuropathological findings
43. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics
44. Neuronal and glial somal size in the prefrontal cortex: A postmortem morphometric study of schizophrenia and Huntington disease
45. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
46. Brain banking and the human hypothalamus-factors to match for, pitfalls and potentials
47. Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients
48. An anatomy of schizophrenia?
49. Decreased GAD67 mRNA expression in a subset of prefrontal cortical GABA neurons in subjects with schizophrenia
50. Stereological methods for estimating total number of neurons and synapses: Issues of precision and bias
51. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia
52. Enzyme activities in relation to pH and lactate in post mortem brain in Alzheimer type and other dementias
53. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia